Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering approaches that bring nanophysics to the heart of the cell. The Nanobiotix philosophy is rooted in designing physics-based, highly effective and generalized solutions that address unmet medical needs and significantly change patient outcomes. 
Nanobiotix’s first-in-class technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients and has now received European market approval. The company’s immuno-oncology program, in partnership with centers including MD Anderson at the University of Texas, has the potential to create a new dimension for cancer immunotherapies. 
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.